Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

NET INCOME (LOSS) PER SHARE (Tables)

NET INCOME (LOSS) PER SHARE (Tables)

9 Months Ended

Sep. 30, 2024

NET INCOME (LOSS) PER SHARE

Schedule of computation of basic and diluted earnings per share


		Three Months Ended September 30,						Nine Months Ended September 30,
		2024			2023			2024			2023
EPS Numerator:
Net income (loss)		$	12,421		$	(5,692)		$	3,144		$	(25,828)
EPS Denominator—Basic:
Weighted-average common shares outstanding			17,600			17,436			17,556			17,389
EPS Denominator—Diluted:
Weighted-average common shares outstanding			17,600			17,436			17,556			17,389
Dilutive effect of stock options, RSUs and shares under Purchase Plan			48			—			43			—
Weighted-average shares outstanding and common stock equivalents			17,648			17,436			17,599			17,389

Net income (loss) per share
Basic		$	0.71		$	(0.33)		$	0.18		$	(1.49)
Diluted		$	0.70		$	(0.33)		$	0.18		$	(1.49)

Schedule of antidilutive securities


		Three Months Ended September 30,						Nine Months Ended September 30,
		2024			2023			2024			2023
Stock options			3,667			3,428			3,668			3,428
RSUs			107			193			110			193
Shares under Purchase Plan			22			30			22			30
Total			3,796			3,651			3,800			3,651